Global Natural Killer Cell Therapy 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR072512336

Publication Date:

July 24, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Natural Killer Cell Therapy market size was valued at US$ 405 million in 2024 and is forecast to a readjusted size of USD 1760 million by 2031 with a CAGR of 23.6% during review period.
Cell therapy, a new therapeutic approach that uses a patient"s own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body"s first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.
The Americas natural killer cells therapeutics market share accounted for the highest share 52.3% in 2019.
Based on application, the market is classified into cancer, gastrointestinal diseases and others. The cancer segment accounted for a major share in 2019 (66.99%).
Major players operating in the market include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics and etc. The Top 6 players accounted for 96.66% of the global revenue market share in 2019.
This report is a detailed and comprehensive analysis for global Natural Killer Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Natural Killer Cell Therapy market size and forecasts, in consumption value ($ Million), 2020-2031
Global Natural Killer Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Natural Killer Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Natural Killer Cell Therapy market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Natural Killer Cell Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Natural Killer Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Glycostem Therapeutics, Fate Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, Nkarta Therapeutics, NantKwest, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Natural Killer Cell Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
NK Cell Therapies
NK Cell Directed Antibodies
麻豆原创 segment by Application
Cancer
Gastrointestinal Diseases
Others
麻豆原创 segment by players, this report covers
Nektar Therapeutics
Innate Pharma SA
Affimed
Chipscreen Biosciences
Glycostem Therapeutics
Fate Therapeutics
Dragonfly Therapeutics
Kiadis Pharma
Nkarta Therapeutics
NantKwest
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Natural Killer Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Natural Killer Cell Therapy, with revenue, gross margin, and global market share of Natural Killer Cell Therapy from 2020 to 2025.
Chapter 3, the Natural Killer Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Natural Killer Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Natural Killer Cell Therapy.
Chapter 13, to describe Natural Killer Cell Therapy research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Natural Killer Cell Therapy by Type
1.3.1 Overview: Global Natural Killer Cell Therapy 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Natural Killer Cell Therapy Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 NK Cell Therapies
1.3.4 NK Cell Directed Antibodies
1.4 Global Natural Killer Cell Therapy 麻豆原创 by Application
1.4.1 Overview: Global Natural Killer Cell Therapy 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Cancer
1.4.3 Gastrointestinal Diseases
1.4.4 Others
1.5 Global Natural Killer Cell Therapy 麻豆原创 Size & Forecast
1.6 Global Natural Killer Cell Therapy 麻豆原创 Size and Forecast by Region
1.6.1 Global Natural Killer Cell Therapy 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Natural Killer Cell Therapy 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Natural Killer Cell Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Natural Killer Cell Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Natural Killer Cell Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Natural Killer Cell Therapy 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Natural Killer Cell Therapy 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Nektar Therapeutics
2.1.1 Nektar Therapeutics Details
2.1.2 Nektar Therapeutics Major Business
2.1.3 Nektar Therapeutics Natural Killer Cell Therapy Product and Solutions
2.1.4 Nektar Therapeutics Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Nektar Therapeutics Recent Developments and Future Plans
2.2 Innate Pharma SA
2.2.1 Innate Pharma SA Details
2.2.2 Innate Pharma SA Major Business
2.2.3 Innate Pharma SA Natural Killer Cell Therapy Product and Solutions
2.2.4 Innate Pharma SA Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Innate Pharma SA Recent Developments and Future Plans
2.3 Affimed
2.3.1 Affimed Details
2.3.2 Affimed Major Business
2.3.3 Affimed Natural Killer Cell Therapy Product and Solutions
2.3.4 Affimed Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Affimed Recent Developments and Future Plans
2.4 Chipscreen Biosciences
2.4.1 Chipscreen Biosciences Details
2.4.2 Chipscreen Biosciences Major Business
2.4.3 Chipscreen Biosciences Natural Killer Cell Therapy Product and Solutions
2.4.4 Chipscreen Biosciences Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Chipscreen Biosciences Recent Developments and Future Plans
2.5 Glycostem Therapeutics
2.5.1 Glycostem Therapeutics Details
2.5.2 Glycostem Therapeutics Major Business
2.5.3 Glycostem Therapeutics Natural Killer Cell Therapy Product and Solutions
2.5.4 Glycostem Therapeutics Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Glycostem Therapeutics Recent Developments and Future Plans
2.6 Fate Therapeutics
2.6.1 Fate Therapeutics Details
2.6.2 Fate Therapeutics Major Business
2.6.3 Fate Therapeutics Natural Killer Cell Therapy Product and Solutions
2.6.4 Fate Therapeutics Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Fate Therapeutics Recent Developments and Future Plans
2.7 Dragonfly Therapeutics
2.7.1 Dragonfly Therapeutics Details
2.7.2 Dragonfly Therapeutics Major Business
2.7.3 Dragonfly Therapeutics Natural Killer Cell Therapy Product and Solutions
2.7.4 Dragonfly Therapeutics Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Dragonfly Therapeutics Recent Developments and Future Plans
2.8 Kiadis Pharma
2.8.1 Kiadis Pharma Details
2.8.2 Kiadis Pharma Major Business
2.8.3 Kiadis Pharma Natural Killer Cell Therapy Product and Solutions
2.8.4 Kiadis Pharma Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Kiadis Pharma Recent Developments and Future Plans
2.9 Nkarta Therapeutics
2.9.1 Nkarta Therapeutics Details
2.9.2 Nkarta Therapeutics Major Business
2.9.3 Nkarta Therapeutics Natural Killer Cell Therapy Product and Solutions
2.9.4 Nkarta Therapeutics Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Nkarta Therapeutics Recent Developments and Future Plans
2.10 NantKwest
2.10.1 NantKwest Details
2.10.2 NantKwest Major Business
2.10.3 NantKwest Natural Killer Cell Therapy Product and Solutions
2.10.4 NantKwest Natural Killer Cell Therapy Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 NantKwest Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Natural Killer Cell Therapy Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Natural Killer Cell Therapy by Company Revenue
3.2.2 Top 3 Natural Killer Cell Therapy Players 麻豆原创 Share in 2024
3.2.3 Top 6 Natural Killer Cell Therapy Players 麻豆原创 Share in 2024
3.3 Natural Killer Cell Therapy 麻豆原创: Overall Company Footprint Analysis
3.3.1 Natural Killer Cell Therapy 麻豆原创: Region Footprint
3.3.2 Natural Killer Cell Therapy 麻豆原创: Company Product Type Footprint
3.3.3 Natural Killer Cell Therapy 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Natural Killer Cell Therapy Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Natural Killer Cell Therapy 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Natural Killer Cell Therapy Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Natural Killer Cell Therapy 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Natural Killer Cell Therapy Consumption Value by Type (2020-2031)
6.2 North America Natural Killer Cell Therapy 麻豆原创 Size by Application (2020-2031)
6.3 North America Natural Killer Cell Therapy 麻豆原创 Size by Country
6.3.1 North America Natural Killer Cell Therapy Consumption Value by Country (2020-2031)
6.3.2 United States Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Natural Killer Cell Therapy Consumption Value by Type (2020-2031)
7.2 Europe Natural Killer Cell Therapy Consumption Value by Application (2020-2031)
7.3 Europe Natural Killer Cell Therapy 麻豆原创 Size by Country
7.3.1 Europe Natural Killer Cell Therapy Consumption Value by Country (2020-2031)
7.3.2 Germany Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Natural Killer Cell Therapy Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Natural Killer Cell Therapy Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Natural Killer Cell Therapy 麻豆原创 Size by Region
8.3.1 Asia-Pacific Natural Killer Cell Therapy Consumption Value by Region (2020-2031)
8.3.2 China Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Natural Killer Cell Therapy Consumption Value by Type (2020-2031)
9.2 South America Natural Killer Cell Therapy Consumption Value by Application (2020-2031)
9.3 South America Natural Killer Cell Therapy 麻豆原创 Size by Country
9.3.1 South America Natural Killer Cell Therapy Consumption Value by Country (2020-2031)
9.3.2 Brazil Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Natural Killer Cell Therapy Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Natural Killer Cell Therapy Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Natural Killer Cell Therapy 麻豆原创 Size by Country
10.3.1 Middle East & Africa Natural Killer Cell Therapy Consumption Value by Country (2020-2031)
10.3.2 Turkey Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Natural Killer Cell Therapy 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Natural Killer Cell Therapy 麻豆原创 Drivers
11.2 Natural Killer Cell Therapy 麻豆原创 Restraints
11.3 Natural Killer Cell Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Natural Killer Cell Therapy Industry Chain
12.2 Natural Killer Cell Therapy Upstream Analysis
12.3 Natural Killer Cell Therapy Midstream Analysis
12.4 Natural Killer Cell Therapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Nektar Therapeutics
Innate Pharma SA
Affimed
Chipscreen Biosciences
Glycostem Therapeutics
Fate Therapeutics
Dragonfly Therapeutics
Kiadis Pharma
Nkarta Therapeutics
NantKwest

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.